Arcus Biosciences Inc [RCUS] stock is trading at $15.31, down -0.52%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RCUS shares have lost -0.52% over the last week, with a monthly amount drifted -6.19%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on November 18, 2022, when BofA Securities initiated its Neutral rating and assigned the stock a price target of $33. Previously, Morgan Stanley started tracking the stock with Overweight rating on October 11, 2022, and set its price target to $40. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $50 on November 24, 2020. Evercore ISI initiated its recommendation with a Outperform. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 03, 2020, and assigned it a price target of $21. In a note dated March 04, 2020, Barclays initiated an Overweight rating and provided a target price of $24 on this stock.
Arcus Biosciences Inc [RCUS] stock has fluctuated between $12.95 and $20.31 over the past year. Currently, Wall Street analysts expect the stock to reach $35.2 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $15.31 at the most recent close of the market. An investor can expect a potential return of 129.92% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Arcus Biosciences Inc [NYSE:RCUS] reported sales of 247.00M for the trailing twelve months, which represents a growth of 34.48%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.19%, Pretax Profit Margin comes in at -1.0%, and Net Profit Margin reading is -1.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.43 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.93 points at the first support level, and at 14.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.87, and for the 2nd resistance point, it is at 16.44.
Ratios To Look Out For
For context, Arcus Biosciences Inc’s Current Ratio is 5.14. In addition, the Quick Ratio stands at 5.14 and the Cash Ratio stands at 0.78. Considering the valuation of this stock, the price to sales ratio is 5.67, the price to book ratio is 2.20.
Transactions by insiders
Recent insider trading involved Azoy Alexander, Chief Accounting Officer, that happened on Aug 13 ’24 when 1357.0 shares were sold. Chief Operating Officer, Jarrett Jennifer completed a deal on Mar 27 ’24 to sell 11551.0 shares. Meanwhile, Chief Operating Officer Jarrett Jennifer sold 13449.0 shares on Mar 18 ’24.
